NCT00055809 arm group b69c30ecd41c9bbef0344878ef16a7d3 [clinicaltrials_resource:NCT00055809/arm-group/b69c30ecd41c9bbef0344878ef16a7d3]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00055809 arm group b69c30ecd41c9bbef0344878ef16a7d3 [clinicaltrials_resource:NCT00055809/arm-group/b69c30ecd41c9bbef0344878ef16a7d3]
Bio2RDF identifier
NCT00055809/arm-group/b69c30ecd41c9bbef0344878ef16a7d3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 9c30ecd41c9bbef0344878ef16a7d3
description [clinicaltrials_vocabulary:description]
Patients receive bevacizumab IV on day 1.
identifier
clinicaltrials_resource:NCT00055809/arm-group/b69c30ecd41c9bbef0344878ef16a7d3
title
NCT00055809 arm group b69c30ecd41c9bbef0344878ef16a7d3
@en
type
label
NCT00055809 arm group b69c30ec ...... c30ecd41c9bbef0344878ef16a7d3]
@en